Medical Affairs Reputations (US) [HIV]
Survey shows medical affairs teams must be more active and provide better information
Doctors say medical affairs teams for 10 major HIV treatments could be doing a better job. In the past 6 months, only one of those teams reached out to more than 70% of the infectious disease specialists we surveyed. Survey respondents also had a lot to say about how teams can improve the information they provide, and the way they provide it—feedback that can help teams build better relationships with doctors.
Find out what your team gets right, and where it’s going wrong in Medical Affairs Reputations: HIV (US).
Comparing 10 major HIV treatments from Bristol-Myers Squibb, Gilead, Janssen, Merck & Co., and ViiV Healthcare, this report reveals:
Interested in the European market? Click here to see the EU5 Edition.
Top Takeaways
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams—answering important questions like:
What do doctors need?
We surveyed 100 US infectious disease specialists, chosen from the largest community of validated physicians in the world.
All respondents:
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
ABOUT FIRSTWORD
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Doctors say medical affairs teams for 10 major HIV treatments could be doing a better job. In the past 6 months, only one of those teams reached out to more than 70% of the infectious disease specialists we surveyed. Survey respondents also had a lot to say about how teams can improve the information they provide, and the way they provide it—feedback that can help teams build better relationships with doctors.
Find out what your team gets right, and where it’s going wrong in Medical Affairs Reputations: HIV (US).
Comparing 10 major HIV treatments from Bristol-Myers Squibb, Gilead, Janssen, Merck & Co., and ViiV Healthcare, this report reveals:
- How infectious disease specialists rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important, and what you can do to improve them.
- How, and how often doctors want to meet with your team.
Interested in the European market? Click here to see the EU5 Edition.
Top Takeaways
- Teams could be more active: Half of the surveyed teams interacted with less than 60% of the surveyed doctors in the past 6 months.
- Doctors aren’t getting all the information they need: They identified 3 ways teams can improve information provision, and highlighted 3 specific types of information they want more of.
- Four teams have the same weakness: Find out which specific medical affairs service they all need to improve.
- On the right frequency: The surveyed teams tend to be reaching out to doctors about as often as doctors would like. Just how often is that?
- X factor: Which team earned a top-3 overall quality rating despite low performance and satisfaction scores on most individual services?
- “Don’t call us…”: Less than 10% for surveyed doctors prefer to be contacted by phone. So how should you get in touch when face-to-face meetings aren’t possible?
- Descovy (emtricitabine/tenofovir alafenamide; Gilead)
- Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
- Isentress (raltegravir; Merck & Co.)
- Prezcobix (darunavir/cobicistat; Janssen)
- Prezista (darunavir; Janssen)
- Reyataz (atazanavir; Bristol-Myers Squibb)
- Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate; Gilead)
- Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
- Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)
- Viread (tenofovir disoproxil fumarate; Gilead)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams—answering important questions like:
What do doctors need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
We surveyed 100 US infectious disease specialists, chosen from the largest community of validated physicians in the world.
All respondents:
- Have been practicing for between 3 and 35 years
- See at least 5 patients with HIV in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
ABOUT FIRSTWORD
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
